La Jolla Pharmaceutical Company and the George Washington University Enter Into Agreement for Technology Related to LJPC-501

SAN DIEGO--()--La Jolla Pharmaceutical Company (NASDAQ: LJPC) (the “Company” or “La Jolla”), a biotechnology company developing therapeutics targeting significant unmet, life-threatening diseases, today announced that it has signed an option agreement with the George Washington University (“GW”) that will add proprietary technology to the Company’s LJPC-501 program.

“We look forward to working with the George Washington University to develop their technology related to LJPC-501,” said George Tidmarsh, President and CEO of La Jolla. “As we continue to expand our product portfolio, we remain committed to helping patients with severe diseases for which no treatment is available.”

The option agreement with GW adds potential proprietary protection to La Jolla’s pipeline, which includes treatments for chronic kidney disease, hepatorenal syndrome, chronic iron overload, and rare diseases.

About La Jolla Pharmaceutical Company

La Jolla Pharmaceutical Company is a biopharmaceutical company focused on the discovery, development and commercialization of innovative therapeutics for chronic organ failure and cancer. GCS-100, the Company's lead product candidate, is a first-in-class inhibitor of galectin-3, a novel molecular target implicated in chronic organ failure and cancer. LJPC-501, the Company’s second product candidate, is a natural peptide for the treatment of hepatorenal syndrome. LJPC-401, the Company’s third product candidate, is a natural peptide for the treatment of iron overload. For more information on the Company please visit http://www.ljpc.com.

Forward Looking Statement Safe Harbor

This document contains forward-looking statements as that term is defined in the Private Securities Litigation Reform Act of 1995. These statements relate to future events or our future results of operations. These statements are only predictions and involve known and unknown risks, uncertainties and other factors, which may cause actual results to be materially different from these forward-looking statements. The Company cautions readers not to place undue reliance on any such forward-looking statements, which speak only as of the date they were made. Certain of these risks, uncertainties, and other factors are described in greater detail in the Company's filings with the U.S. Securities and Exchange Commission (“SEC”), all of which are available free of charge on the SEC's web site http://www.sec.gov. These risks include, but are not limited to, risks relating to the development of GCS-100, LJPC-501 and LJPC-401, the success and timing of future preclinical and clinical studies of these compounds, and potential indications for which GCS-100, LJPC-501 and LJPC-401 may be developed. Subsequent written and oral forward-looking statements attributable to the Company or to persons acting on its behalf are expressly qualified in their entirety by the cautionary statements set forth in the Company's reports filed with the SEC. The Company expressly disclaims any intent to update any forward-looking statements.

Contacts

Company Contact
La Jolla Pharmaceutical Company
George F. Tidmarsh, M.D., Ph.D.
President & Chief Executive Officer
Phone: 858-207-4264
Email: GTidmarsh@ljpc.com
and
La Jolla Pharmaceutical Company
Chester S. Zygmont, III
Director of Finance
Phone: 858-207-4262
Email: czygmont@ljpc.com

Release Summary

La Jolla Pharmaceutical Company and the George Washington University Enter into Agreement for Technology Related to LJPC-501

Sharing

Contacts

Company Contact
La Jolla Pharmaceutical Company
George F. Tidmarsh, M.D., Ph.D.
President & Chief Executive Officer
Phone: 858-207-4264
Email: GTidmarsh@ljpc.com
and
La Jolla Pharmaceutical Company
Chester S. Zygmont, III
Director of Finance
Phone: 858-207-4262
Email: czygmont@ljpc.com